Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 293

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 293
---
 REM-001 for cutaneous metastatic breast cancer (“CMBC”).

| 4 | Clinical trials grant |

Effective July 1, 2023, the Company was awarded a $ 2,000 Small Business Innovation Research grant from the National Institutes of Health (“NIH”) to support the clinical development of REM-001 for the treatment of cutaneous metastatic breast cancer. The grant will be received in two tranches: approximately $ 1,250 for the period July 1, 2023, to June 30, 2024, and approximately $ 750 for the period July 1, 2024, to June 30, 2025. As a result of receiving the grant, the REM-001, 15-patient clinical trial will be re-started. The grant is expended to the Company as a reimbursement of expenditures incurred. During the three and six months ended December 31, 2023, the Company received $ 197 (2022 - nil ) and $ 210 (2022 - nil ), respectively, for grants received against research and development expenditures in the period.

The grant is subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.

F-5 6

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

| 5 | Property and equipment, net |

| Balance, June 30, 2023     |     | $(thousands) | 709 |   |
|:---------------------------|:----|:-------------|----:|:--|
| Additions                  |     |              |  20 |   |
| Depreciation               |     |              | (30 | ) |
| Balance, December 31, 2023 |     |              | 699 |   |

At December 31, 2023, the total capitalized cost of property and equipment was $ 879 (June 30, 2023 - $ 859 ), of which $ 699 is not in use. The Company has recognized $ 30 in depreciation expense, respectively, for each of the six months ended December 31, 2023, and 2022, on